

Chiara Dentone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4824643/publications.pdf>

Version: 2024-02-01

7
papers

141
citations

1478505

6
h-index

1720034

7
g-index

7
all docs

7
docs citations

7
times ranked

208
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors Associated With Weight Gain in People Treated With Dolutegravir. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa195.	0.9	47
2	Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 289-294.	2.5	24
3	<p>The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 5515-5520.	4.3	24
4	<p>Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project</p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1385-1391.	2.7	19
5	Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. <i>AIDS Patient Care and STDs</i> , 2021, 35, 342-353.	2.5	15
6	Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 19-26.	1.1	6
7	<p>Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort</p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 2291-2300.	2.7	6